FindTrial
Sign In

To assess occurrence of peripheral neuropathy in taxane based chemotherapy in patients having Epithelial ovarian cancer.

â??A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinomaâ??

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/09/009603
Enrollment
100
Registered
2017-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Literate spithelial Ca Ovary patients ECOG 0-2 age more than 18 who will be receiving taxane based chemo in adjuvant and neoadjuvant settings

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)1. Patients diagnosed with epithelial ovarian carcinoma receiving taxane based chemotherapy in neoadjuvant & adjuvant 2. ECOG PS 0-2 at study entry 3. Patients willing to participate in the Study. 4. Literate patients who can read the translated questionnaires. 5. Age more than 18 years

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

MeasureTime frame
To measure the cumulative fraction of patients having each grade of Peripheral Neuropathy up to 6 months after completion of last cycle of chemotherapy.Timepoint: The patients will be evaluated at baseline, then after 3 cycle, after 6 cycle and after 6 months after completion of chemotherapy—

Secondary

MeasureTime frame
1.Fraction of patients with PN at different time intervals. 2.Impact of co-variates on cumulative incidence of PN in a logistic regression model -Age,urban, anaemia vitB12, folic acid vitD, DM, HTN,HIV infection , medications,CBC,LFT,Rft. 3.To document the percentage of patients with adverse Quality of life due to Taxane based chemotherapy of Epithelial ovarian cancer.Timepoint: The patients will be evaluated at baseline, then after 3 cycle, after 6 cycle and after 6 months after completion of chemotherapy—

Countries

India

Contacts

Public ContactDr Sudeep Gupta

Tata Memorial Centre

dr.swarnabindubanerjee@gmail.com0224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026